Extended-release naltrexone to prevent opioid relapse in criminal justice offenders

New England Journal of Medicine

Volumn 374, Issue 13, 2016, Pages 1232-1242

  Lee, Joshua D ^a,b   Friedmann, Peter D ^d   Kinlock, Timothy W ^e,f   Nunes, Edward V ^c   Boney, Tamara Y ^h   Hoskinson, Randall A ^d   Wilson, Donna ^d   McDonald, Ryan ^a   Rotrosen, John ^a   Gourevitch, Marc N ^a   Gordon, Michael ^e   Fishman, Marc ^e,g   Chen, Donna T ^j   Bonnie, Richard J ^k   Cornish, James W ^h,i   Murphy, Sean M ^j,l   O'Brien, Charles P ^h  

^a NEW YORK UNIVERSITY   (United States)

^b Division of General Internal Medicine and Clinical Innovation   (United States)

^c New York State Psychiatric Institute ^*  (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF BALTIMORE   (United States)

^f School of Criminal Justice   (United States)

^g Center of Maryland   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j School of Medicine   (United States)

^k UNIVERSITY OF VIRGINIA SCHOOL OF LAW   (United States)

^l WASHINGTON STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; DELAYED RELEASE FORMULATION; NARCOTIC ANTAGONIST;

ABSCESS; ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COCAINE DEPENDENCE; COMMUNITY PROGRAM; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DEPRESSION; DRUG FATALITY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INJECTION SITE REACTION; INSOMNIA; INTRAVENOUS DRUG ABUSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MUSCULOSKELETAL DISEASE; OFFENDER; OPEN STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SELF REPORT; SEX DIFFERENCE; SEXUAL BEHAVIOR; SUICIDE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; CLINICAL TRIAL; COMMUNITY CARE; COMPARATIVE STUDY; COMPLICATION; COUNSELING; DELAYED RELEASE FORMULATION; DRUG OVERDOSE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; OPIOID-RELATED DISORDERS; SECONDARY PREVENTION; SUBSTANCE ABUSE;

ADULT; COMMUNITY HEALTH SERVICES; COUNSELING; CRIMINALS; DELAYED-ACTION PREPARATIONS; DRUG OVERDOSE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SECONDARY PREVENTION; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84962418004     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1505409     Document Type: Article

References (26)

1. Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med 2013; 159: 592-600.
2. Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend 2009;99:222-30.
3. Gordon MS, Kinlock TW, Schwartz RP, et al. Buprenorphine treatment for probationers and parolees. Subst Abus 2015;36:217-25.
4. Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O'Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug A lcohol Depend 2014;142:33-40.
5. Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction 2008;103:1333-42.
6. Lee JD, Rich JD. Opioid pharmaco-therapy in criminal justice settings: now is the time. Subst Abus 2012; 33: 1-4.
7. Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA 2009; 301: 183-90.
8. Nunn A, Zaller N, Dickman S, Trim-bur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend 2009;105:83-8.
9. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psy-chopharmacology (Berl) 2002;159:351-60.
10. Bigelow GE, Preston KL, Schmittner J, Dong Q, Gastfriend DR. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend 2012;123:57-65.
11. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 210-8.
12. Krupitsky E, Nunes E V, Ling W, Illepe-ruma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011;377:1506-13.
13. Coviello DM, Cornish JW, Lynch KG, et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus 2012; 33: 48-59.
14. Lee JD, Friedmann PD, Boney TY, et al. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials 2015; 41: 110-7.
15. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 2000.
16. Stout RL, Wirtz PW, Carbonari JP, Del Boca FK. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Suppl 1994; 1 2:70-5.
17. U.S. Department of Veterans Affairs Office of Research and Development, CSP Coordinating Center-Perry Point, MD (http://www.research.va.gov/programs/csp/perrypoint.cfm).
18. Lee JD, Grossman E, DiRocco D, et al. Extended-release naltrexone for treatment of alcohol dependence in primary care. J Subst Abuse Treat 2010; 39: 14-21.
19. Sobell LC, Sobell MB. Alcohol time-line followback users' manual. Toronto: Addiction Research Foundation, 1995.
20. Watkins KE, Metzger D, Woody G, McLellan AT. High-risk sexual behaviors of intravenous drug users in-and out-of-treatment: implications for the spread of HIV infection. Am J Drug Alcohol Abuse 1992;18:389-98.
21. Nurco DN, Kinlock T, Balter MB. The severity of preaddiction criminal behavior among urban, male narcotic addicts and two nonaddicted control groups. J Res Crime Delinq 1993;30:293-316.
22. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199-213.
23. Alkermes. Full prescribing information: VIVITROL (naltrexone for extended-release injectable suspension), revised July 2013 (http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021897s020s023lbl.pdf).
24. Kjome KL, Moeller FG. Long-acting injectable naltrexone for the management of patients with opioid dependence. Subst Abuse 2011;5:1-9.
25. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-95.
26. Lee JD, McDonald R, Grossman E, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction 2015; 110: 1008-14.